Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

By | December 9, 2021
Researchers have developed Nanocovax, a COVID-19 subunit vaccine based on recombinant protein technology to produce the extracellular (soluble) portion of the S protein of SARS-CoV-2.